中国汉族人S-美芬妥英4′-羟化代谢的遗传多态性(英文)

目的:研究我国汉族人S-美芬妥英(S-Mep)4′-羟化代谢的遗传多态性。方法:148名互无血缘关系的汉族健康志愿者和5个家族21名成员,口服美芬妥英100mg后,用HPLC法测定0-12h尿中S-Mep 4′-羟化代谢的代谢比值(lg MR)和羟化指数(lg HI)。结果:lg MR和lg HI均呈两态性分布,分型点(antimode)分别为-1.00和1.50,羟化代谢缺陷的频发率为13.5％(20/148)。系谱分析表明S-Mep 4′-羟化代谢缺陷为常染色体隐性遗传。结论:S-Mep 4′-羟化代谢缺陷频发率东方人高于高加索人,遗传方式均为常染色体隐性遗传。     

HPLC法测定解酒灵冲剂中葛根素的含量

应用ＨＰＬＣ法测定解酒灵冲剂中葛根素的含量，该方法简便、准确、重现性好，可作为该制剂控制质量标准的含量测定方法     

从“化学成分谱-减毒作用谱-生物信息谱”关联分析整体评价雷公藤配伍金钱草的相杀减毒作用机制

目的:整体评价雷公藤(LGT)配伍金钱草(JQC)后在荷瘤状态下的相杀减毒作用机制。方法:以配伍前后12个差异特征成分为化学成分谱,以丙氨酸氨基转移酶(ALT),天门冬氨酸氨基转移酶(AST),肌酐(Cr)和尿素氮(BUN),肝丙二醛(MDA),肾MDA共6指标为减毒作用谱,以肝和肾的谷胱甘肽(GSH),谷胱甘肽-S-转移酶(GST),谷胱甘肽过氧化物酶(GPx),超氧化物歧化酶(SOD),过氧化氢酶(CAT),白细胞介素(IL)-10共12个生物指标作为生物信息谱,通过主成分分析(PCA)整体评价LGT-JQC在荷瘤S180和H22肿瘤状态下的相杀减毒作用及其机制,通过对"化学成分谱-减毒作用谱-生物信息谱"灰色关联分析(GCA)评价化学成分和生物指标对其相杀减毒作用的贡献大小。结果:与模型组比较,LGT单用后使S180和H22的减毒作用谱得分Z_1值和Z_3值均显著升高(P0.01);与LGT单用组比较,LGT-JQC在质量配比为4∶1,2∶1,1∶1,1∶2,1∶4配伍时均能显著降低LGT引起的过高水平的Z_1值和Z_3值(P0.01);LGT-JQC在质量比为4∶1,1∶1,1∶2,1∶4配伍时的Z_1值和Z_3值均明显高于质量比在2∶1时相应的Z_1值和Z_3值(P0.01)。LGT能使S180和H22荷瘤状态下生物信息谱得分Z_2值和Z_4值均显著降低,配伍JQC可使Z_2值和Z_4值显著升高。对二者在S180和H22肿瘤状态下相杀减毒作用贡献最大的化学成分分别为3#和10#特征成分,贡献最大的生物指标分别为肾GPx和肾GSH。结论:LGT和JQC在质量比为4∶1~1∶4配伍时,对LGT所致的荷瘤S180和H22肿瘤状态下的毒性均有减毒作用,二者相杀减毒的最佳配比均为2∶1,减毒作用体现了中医"有故无殒"思想,其减毒作用机制涉及肝、肾的抗氧化损伤及抗炎症反应,其中尤以肾GPx(S180)和肾GSH(H22)对减毒作用机制的贡献最大。     

不同剂量亚砷酸钠染毒大鼠多药耐药相关蛋白2表达水平的变化

目的观察不同剂量亚砷酸钠染毒大鼠肝细胞膜转运蛋白——多药耐药相关蛋白2(multidrugresistance-associatedprotein2,MRP2)表达水平的变化及与砷代谢的关系。方法24只健康雄性Wistar大鼠随机分为4组:第1组为对照组,给予生理盐水;第2～4组为染砷组,分别给予4、10和20mg/kg体质量的亚砷酸钠溶液,隔天灌胃染毒1次,2周后将大鼠处死。原子吸收分光光度法测定胆汁、全血和肝组织中的总砷含量。蛋白印记法测定肝细胞膜上MRP2的改变。结果经方差分析检验,胆汁和肝脏中含砷量随着染砷剂量的增加而逐渐增加(P<0.05)。两两比较发现,3个染毒组的血砷与对照组之间差异有统计学意义,而3个染毒组间差异无统计学意义。随着染砷剂量增加,MRP2表达有增加的趋势,且MRP2表达量与胆汁含砷量呈正相关(r=0.986,P<0.05)。结论亚砷酸钠可以诱导MRP2的表达,随染砷剂量增加,MRP2表达量增加。MRP2在砷及其代谢产物的胆汁排泄过程中发挥了重要作用。     

解毒活血法对急性冠脉综合征患者PCI术后P-选择素的表达的影响

目的:观察解毒活血中药对急性冠脉综合症患者PC I术后P-选择素的表达的影响。方法:将50例急性冠脉综合征PC I术后患者随机分为治疗组和对照组两组,每组25例,对照组25例予常规西药治疗,治疗组患者在对照组治疗基础上加予活血解毒中药治疗,检测治疗前后血清中P-选择素的表达水平。结果:治疗组P-选择素表达水平均较对照组显著降低,P<0.05;治疗组的临床疗效优于对照组,治疗组总有效率为92%,对照组总有效率为72%,P<0.05。结论:解毒活血中药能明显降低急性冠脉综合征患者PC I术后血清P-选择素的表达水平,表明解毒活血中药能抑制PC I术后炎性反应,对于急性冠脉综合症的治疗和预后显示出一定价值。     

清热解毒法对干燥综合征干预的实验研究

目的:探讨清热解毒法对SS模型鼠的疗效。方法:复制SS动物模型,设立模型组1组及治疗组10组,即白花蛇舌草组、紫草组、青蒿组、蒲公英组、大青叶组、板蓝根组、半枝莲组、玄参组、积雪草组、七叶一枝花组;通过不同清热解毒中药对SS模型小鼠体重、饮水量、唾液流量以及颌下腺指数的影响来观察清热解毒法对SS小鼠的治疗作用。结果:通过不同清热解毒中药的干预,SS模型鼠体重、饮水量、唾液流量以及颌下腺指数均得到改善。结论:清热解毒法可以通过体重、饮水量、唾液流量以及颌下腺指数的改善来发挥对SS小鼠的治疗作用。     

不同浓度健脾解毒中药对肝癌裸鼠的抗癌作用

[目的]探讨不同浓度健脾解毒中药对间接原位移植肝癌裸鼠模型的抗癌作用及最佳药效浓度。[方法]采用人肝细胞癌细胞株Bel-7402间接原位移植,造雄性肝癌裸鼠模型90只,造模后24h随机分9组,即不同浓度健脾解毒复方中药A、B、C、D、E、F、G组,替加氟207化疗（FT）组,0．85％氯化钠（NS）组,8周后处死裸鼠,观察各组荷瘤裸鼠的生存时间、体重变化、肿瘤形成情况、肝脾指数等。另外10只雄性裸鼠不造模作为正常对照（DZ）组。[结果]造模成功率为76．14％,实验结束获得有效病理标本67例,成瘤以多发小结节为主;各中药组的生存时间和生存率均优于FT组（P〈0．05）,中药D、E组的生存时间〉NS组（P〈0．05）;各中药组荷瘤裸鼠治疗后体重有增加（P〈0．05）,FT组治疗后体重明显下降（P〈0．05）;中药组的肝指数和脾指数均〉FT组（P〈0．05）。[结论]健脾解毒复方中药可以增加荷瘤裸鼠的体重,改善营养状态,延长带瘤生存时间。健脾解毒复方中药抗癌作用的有效范围为7．5～20．0g／kg。     

Abstracts

Abstract

A high performance liquid chromatography method has been used to study the plasma kinetics of atrazine in a human fatality after ingestion of a herbicide mix containing atrazine, aminotriazole, ethylene glycol and formaldehyde. A hemodialysis was performed in an effort to eliminate these toxic substances. The mean atrazine clearance over 4?h was 250 mL/min and the dialysance of atrazine was calculated as 76%. On autopsy, the kidney showed the highest concentration of atrazine (97.62 μg/g-¹ wet tissue) with lesser concentrations in the lung, small intestine and liver, and the lowest concentration in the heart.     

Randomized double-blinded and controlled clinical trial on treatment of HIV/AIDS by Zhongyan-4

Objective: To assess the efficacy and safety of Zhongyan-4 (ZY-4, a Chinese herbal preparation worked out according to the therapeutic principle of supplementing qi, nourishing Yin, clearing heat and detoxication) in treating HIV/AIDS patients in the early or middle stage.Methods: Adopted was randomized double-blinded and placebo-parallel-controlled method, with 72 HIV/AIDS patients randomly divided into the ZY-4 group (36 patients) treated with ZY-4 and the control group (36 patients) treated with placebo. The treatment course was six months. The index of CD ₄ ⁺ , CD ₈ ⁺ counts, body weight, clinical symptom scoring were estimated at 4 time points (0, 1, 3 and 6 month in the course), and also the viral load before and after treatment. The whole course of observation was completed in 63 patients, 30 in the ZY-4 group and 33 in the control group.Results: CD ₄ ⁺ count in the ZY-4 group got elevated by 7.70 ± 150.96/mm³ on average, while that in the control group lowered by 27.33 ± 85.28 /mm³. Fifteen out of the 30 patients in the ZY-4 group had their CD ₄ ⁺ count increased, which was evidently much higher than that in the control group (8/33,P<0.05), suggesting that the efficacy of ZY-4 is superior to that of placebo in elevating CD ₄ ⁺ count. Moreover, ZY-4 showed actions in elevating CD₄₅RA⁺ and CD ₈ ⁺ count, reducing HIV virus load, improving clinical symptom/sign and increasing body weight of patients. No obvious adverse reaction was found in the clinical trial.Conclusion: ZY-4 has an immunity-protective and/or rebuilding function in HIV/AIDS patients in the early and middle stage, and also shows effects in lowering viral load, increasing body weight and improving symptoms and signs to a certain degree. Supported by the Projects of Ministry of Science and Technology for 10th Five-year Plan (2001BA701A18)     

解毒排毒法内外合治毒蛇咬伤的临床研究

目的:探讨救治毒蛇咬伤的临床方法。方法:对毒蛇咬伤患者采用中医药解毒排毒法为主的综合治疗方法,观察其临床疗效。结果:69例患者治愈37例,显效16例,有效15例,死亡1例,总有效率98.5%,痊愈显效率76.8%。结论:解毒排毒法内外合治毒蛇咬伤具有良好的疗效。